semaglutide muscle mass loss impacts skeletal to a similar extent as caloric restriction in mice with diet‐induced obesity - Jeromson - The Journal of Physiology Semaglutide Therapy and Accelerated Sarcopenia

Patients with metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) and insulin resistance may experience improvements in hepatic steatosis and liver enzyme elevations, though this represents an off-label use with evolving evidence

The main focus is now back on FDA-approved products that went through strong clinical trials to show they are safe and work well

Rnorodne aspekty semaglutydy rodz niepewnoci

The future of obesity treatment is quality weight loss The next generation of obesity research is increasingly focused on more than total weight loss

Infections were more frequently reported in females than in males (see Table 1)